Skip to main content
SpringerLink
Log in

Rosiglitazone: accusations over cardiovascular safety

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. United States Senate Committee on Finance.Baucus, Grassley Release Finance Committee Report on Diabetes Drug Avandia, Express Concern About FDA's Role in Protecting Patients in Ongoing Avandia Study. Media Release: 20 Feb 2010. Available from: URL: http://finance.senate.gov

  2. GlaxoSmithKline.GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia. Media Release: 20 Feb 2010. Available from: URL: http://www.gsk.com

  3. FDA Food and Drug Administration.FDA Drug Safety Communication: ongoing review of Avandia (rosiglitazone) and cardiovascular safety. Internet Document: [2 pages], 22 Feb 2010. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosiglitazone: accusations over cardiovascular safety. React. Wkly. 1290, 2 (2010). https://doi.org/10.2165/00128415-201012900-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012900-00002

Keywords

Search

Navigation